Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irofulven in Recurrent or Persistent Endometrial Carcinoma
NCT00005031Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Aug 2000
- Primary completion
- Oct 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of irofulven in endometrial carcinoma, sponsored by GOG Foundation. Primary endpoints: Antitumor activity and Toxicity. Started Aug 2000; status: completed.
02
Drugs
irofulven
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT00005031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005031.